Semaglutide
A Study of BGM0504 in Early T2DM With Obesity
Novo Nordisk · Phase 3 · Recruiting · Enrollment 372
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| BGM0504 Injection 15 mg | n/r | n/r | n/r | n/r |
| Semaglutide Injection 1.0 mg | n/r | n/r | n/r | n/r |
Not shown
- BGM0504 Injection 15 mg: endpoint not reported
- Semaglutide Injection 1.0 mg: endpoint not reported